Biotech screening & diligence for venture investors
Early-stage biotech diligence, built on public evidence.
RichStorm is an AI-powered investment research platform for early-stage biotech screening and diligence. It evaluates companies against your investment criteria and builds a structured, source-backed research journey from company verification through full diligence.
Example Therapeutics
Preclinical · Seed · Early-stage mandate
The full public-evidence review is complete. Material questions or upcoming milestones should be resolved before further engagement.
Sources (24) · Based on public information
Consistent
Every company is assessed through the same research stages and standards.
Comparable
Results use a common research vocabulary, making companies easier to evaluate side by side.
Auditable
Findings are tied to the public evidence behind them.
Retrievable
Analyses remain available with their research context and evidence for future review.
How it works
One research journey, four stages, every step visible.
The first three stages establish identity, fit, and screening readiness. Full Diligence starts only when you choose to run it.
Company Verification
Confirms the company identity from public records before research begins.
Investment Criteria Match
Checks development stage, financing stage, and focus against your investment preferences.
Screening
Looks for structural issues across evidence, differentiation, capital needs, and the path to de-risking.
Full Diligence
A deeper public-evidence review across scientific evidence, organization, competitive position, valuation, and exit potential.
Where it fits
Built for the work before the first meeting.
Pipeline screening
Screen companies against your criteria and identify which opportunities warrant deeper attention.
Meeting preparation
Separate what public evidence can establish from the questions that still require discussion or private diligence.
Revisit new evidence
Return to prior research as new public evidence and milestones emerge.
Evidence first
Every conclusion shows its work.
Findings are tied to the public sources behind them. When public evidence cannot answer a question, RichStorm identifies the gap for further diligence rather than treating missing information as negative evidence.
Evidence-supported conclusion
The available public evidence supports the finding, while remaining uncertainties are preserved separately for follow-up.
Research Insights
Featured research & contributor perspectives
340B and Healthcare Investing: How a Drug Pricing Program Can Shape Deal Decisions
Beyond the Weight-Loss Numbers: How New Obesity Drugs Work, How Safe They Are, and What Investors Are Betting On
Anti-Amyloid Finally Worked. What Comes Next?
RichStorm
Start your first research journey.
Set your investment preferences, enter a company, and follow the research from verification through screening and full diligence.